The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $124.99

Today's change-0.06 -0.05%
Updated May 22 12:02 PM EDT. Delayed by at least 15 minutes.
 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $124.99

Today's change-0.06 -0.05%
Updated May 22 12:02 PM EDT. Delayed by at least 15 minutes.

Vertex Pharmaceuticals Inc down slightly

Vertex Pharmaceuticals Inc is down just (U.S.)$0.06 today to (U.S.)$124.99. Shares have lost 0.97% over the last five days, but have gained 5.21% over the last year to date. This security has outperformed the S&P 500 by 63.13% during the last year.

Key company metrics

  • Open(U.S.) $124.91
  • Previous close(U.S.) $125.05
  • High(U.S.) $125.96
  • Low(U.S.) $124.33
  • Bid / Ask(U.S.) $124.99 / (U.S.) $125.02
  • YTD % change+5.21%
  • Volume391,388
  • Average volume (10-day)1,915,500
  • Average volume (1-month)1,702,699
  • Average volume (3-month)1,710,875
  • 52-week range(U.S.) $63.68 to (U.S.) $137.50
  • Beta0.22
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$2.95
Updated May 22 12:02 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-117.92%

Although this company's net profit margin is negative, it is above the industry average and implies that Vertex Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.08%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue139145179138
Total other revenue--------
Total revenue139145179138
Gross profit129133169129
Total cost of revenue9111010
Total operating expense310298321283
Selling / general / administrative86797577
Research & development216201191225
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)-3441-37
Other operating expenses, total3348
Operating income-172-154-142-144
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-198-179-167-159
Income after tax-199-181-170-159
Income tax, total0231
Net income-199-177-170-159
Total adjustments to net income--------
Net income before extra. items-199-176-170-159
Minority interest0400
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-199-176-170-159
Inc. avail. to common incl. extra. items-199-177-170-159
Diluted net income-199-177-170-159
Dilution adjustment--000
Diluted weighted average shares239239236234
Diluted EPS excluding extraordinary itemsvalue per share-0.83-0.74-0.72-0.68
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.84-0.73-0.61-0.78